{"id":36935,"date":"2026-07-15T21:00:00","date_gmt":"2026-07-15T19:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=f87b6df584adf6f93b60a10770925828"},"modified":"2026-07-15T21:00:00","modified_gmt":"2026-07-15T19:00:00","slug":"theraclion-first-half-2026-report-on-the-liquidity-contract-with-credit-industriel-et-commercial-2","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=36935","title":{"rendered":"Theraclion: First Half 2026 Report on the Liquidity Contract With CR\u00c9DIT INDUSTRIEL ET COMMERCIAL"},"content":{"rendered":"<p>MALAKOFF, France--(BUSINESS WIRE)--Regulatory News:<\/p><p>\nTheraclion (Paris:ALTHE):<\/p><p>\nListing venue: Euronext Growth Paris\n<br\/>PEA-PME eligible\n<br\/>ISIN Code: FR0010120402\n<br\/>Website: <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.theraclion.com&amp;esheet=54570919&amp;newsitemid=20260715941809&amp;lan=en-US&amp;anchor=www.theraclion.com&amp;index=1&amp;md5=d0dcdf970671881d079d9286cd9ea4a0\" rel=\"nofollow\" shape=\"rect\">www.theraclion.com<\/a><\/p><p>\nUnder the liquidity contract entrusted by THERACLION to CR\u00c9DIT INDUSTRIEL ET COMMERCIAL, as of June 30, 2026, the following resources were held in the liquidity account:<\/p><ul class=\"bwlistdisc\">\n<li>\n26,499 shares<\/li>\n<li>\n\u20ac3,355.99<\/li>\n<\/ul><p>\nDuring the 1<sup>st<\/sup> half of 2026, a total of the following was traded:<\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>BUY<\/b><\/p><\/td><td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n380,553 shares<\/p><\/td><td class=\"bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwwidth25 bwvertalignt\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n\u20ac234,517.84<\/p><\/td><td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n1,030 transactions<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>SELL<\/b><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n368,894 shares<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwwidth25 bwvertalignt\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n\u20ac225,977.25<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth25\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n955 transactions<\/p><\/td><\/tr>\n<\/table><p>\nIt is recalled that at the time of signing the contract, the following resources were held in the liquidity account:<\/p><ul class=\"bwlistdisc\">\n<li>\n31,850 shares<\/li>\n<li>\n\u20ac27,935.01<\/li>\n<\/ul><p>\n<b>About Theraclion<\/b><\/p><p>\nTheraclion is a French MedTech company committed to developing a non-invasive alternative to surgery through the innovative use of focused ultrasound.\n<br\/>High-Intensity Focused Ultrasound (HIFU) requires no incisions or operating room, leaves no scars and allows patients to immediately resume their daily activities. The HIFU method concentrates therapeutic ultrasound toward an internal focal point from outside the body.\n<br\/>Theraclion is developing Sonovein\u00ae, a HIFU robotic platform for the treatment of varicose veins, CE-marked under MDR (EU 2017\/745), with the potential to replace millions of surgical procedures each year. To date, Sonovein\u00ae has been adopted by more than a dozen centres worldwide and has been used in more than 4,000 procedures. In the United States, Sonovein\u00ae is not yet available for sale.<\/p><p>\nBased in Malakoff (Paris), the Theraclion team consists of approximately 40 people.<\/p><p>\n<b>For more information, please visit <\/b><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.theraclion.com&amp;esheet=54570919&amp;newsitemid=20260715941809&amp;lan=en-US&amp;anchor=www.theraclion.com&amp;index=2&amp;md5=176e77261cb5903c7cae02da4ec74331\" rel=\"nofollow\" shape=\"rect\"><b>www.theraclion.com<\/b><\/a><b> and follow us on <\/b><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Ftheraclion%2F&amp;esheet=54570919&amp;newsitemid=20260715941809&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=d2983ec4ceeea9e7b5eb37278c842184\" rel=\"nofollow\" shape=\"rect\"><b>LinkedIn<\/b><\/a><b>.<\/b><\/p><p>\nTheraclion is listed on Euronext Growth Paris\n<br\/>Eligible for the PEA-PME scheme\n<br\/>Ticker: ALTHE - ISIN Code: FR0010120402\n<br\/>LEI : 9695007X7HA7A1GCYD29<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>Theraclion Contact<\/b><br\/>Martin Deterre\n<br\/>Chief Executive Officer\n<br\/><a  href=\"mailto:contact@theraclion.com\" rel=\"nofollow\" shape=\"rect\">contact@theraclion.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>MALAKOFF, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News:<br \/>\nTheraclion (Paris:ALTHE):<br \/>\nListing venue: Euronext Growth Paris<br \/>\nPEA-PME eligible<br \/>\nISIN Code: FR0010120402<br \/>\nWebsite: www.theraclion.com<br \/>\nUnder the liquidity contract entrusted by THERACLION to CR\u00c9DIT INDUS&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-36935","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/36935","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36935"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/36935\/revisions"}],"predecessor-version":[{"id":36937,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/36935\/revisions\/36937"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36935"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36935"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36935"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}